Summary
Abbott Laboratories reported strong financial performance for the second quarter and first six months of 2021, driven by significant growth across its key business segments, particularly Diagnostics and Medical Devices. Total net sales increased by 39.5% and 37.4% for the three and six-month periods ending June 30, 2021, respectively, compared to the prior year. A substantial portion of this growth was attributed to the continued high demand for Abbott's COVID-19 testing products, which generated $1.3 billion in the second quarter and $3.5 billion in the first six months of 2021. Excluding the impact of COVID-19 testing sales, the company's overall sales still showed robust growth of 33.2% and 19.5% respectively. Profitability was impacted by a significant restructuring charge of $499 million related to aligning COVID-19 diagnostic test manufacturing with evolving demand. Despite this charge, operating earnings saw substantial increases, especially in the Diagnostic Products and Medical Devices segments. The company's financial position remains strong, with an increase in cash and cash equivalents and ample liquidity. Abbott also continued to return value to shareholders through increased dividends and share repurchases, reinforcing its commitment to financial discipline and shareholder returns.
Financial Highlights
51 data points| Revenue | $10.22B |
| Cost of Revenue | $4.95B |
| Gross Profit | $5.28B |
| R&D Expenses | $654.00M |
| SG&A Expenses | $2.73B |
| Operating Expenses | $8.83B |
| Operating Income | $1.39B |
| Interest Expense | $134.00M |
| Net Income | $1.19B |
| EPS (Basic) | $0.67 |
| EPS (Diluted) | $0.66 |
| Shares Outstanding (Basic) | 1.78B |
| Shares Outstanding (Diluted) | 1.79B |
Key Highlights
- 1Abbott Laboratories reported a substantial increase in net sales, with a 39.5% rise in the second quarter and a 37.4% rise in the first six months of 2021, driven by strong performance across all segments.
- 2COVID-19 testing-related sales were a significant growth driver, reaching $1.3 billion in Q2 2021 and $3.5 billion in the first six months of 2021.
- 3Excluding COVID-19 testing sales, overall net sales still demonstrated strong organic growth of 33.2% in Q2 and 19.5% in the first six months of 2021.
- 4A significant restructuring charge of $499 million was recorded in the second quarter of 2021, related to the Diagnostic Products segment's manufacturing network adjustments for COVID-19 tests.
- 5The Medical Devices segment showed robust growth, with notable increases in Diabetes Care (driven by FreeStyle Libre), Structural Heart, and Electrophysiology.
- 6Earnings per share (diluted) increased significantly to $0.66 for the three months ended June 30, 2021, from $0.30 in the prior year period.
- 7Abbott maintained a strong liquidity position, with cash and cash equivalents increasing to $8.7 billion as of June 30, 2021, and continued to return capital to shareholders through dividends and share repurchases.